[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100302213":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":10,"locations":27,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":10,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Vonoprazan 10 mg",null,"The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.",[13],"Drug: Vonoprazan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Vonoprazan","Vonoprazan tablets",[9],[21,22],"Takecab tablets","TAK-438",[24],{"name":25,"affiliation":5,"role":26},"Study Director","STUDY_DIRECTOR",[28],{"facility":29,"status":10,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Takeda Selected Site","Tokyo","Japan","JP",{"type":34,"coordinates":35},"Point",[36,37],139.69171,35.6895,{"lat":37,"lon":36},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100302213","special-drug-use-surveillance-of-vonoprazan-for-prevention-of-recurrence-of-gastricduodenal-ulcer-in-patients-receiving-non-steroidal-anti-inflammatory-drugs-long-term-use-100302213",true,"NCT03214198","Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"","Special Drug Use Surveillance of Takecab Tablets for \"Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"","Inclusion Criteria:\n\n\\- Participants with a history of gastric or duodenal ulcer\n\nExclusion Criteria:\n\n* Participants with gastric or duodenal ulcer at initiation of vonoprazan therapy\n* Participants with active upper gastrointestinal haemorrhage at initiation of vonoprazan therapy\n* Participants with a history of hypersensitivity to any ingredients of vonoprazan Tablets\n* Participants receiving atazanavir sulfate or rilpivirine hydrochloride",false,"ALL",{"count":51,"type":52},1304,"ACTUAL","OBSERVATIONAL","The purpose of this study is to investigate the safety and efficacy of long-term administration of Vonoprazan tablets (Takecab tablets) for up to 12 months in the routine clinical setting in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs).",[56],"A History of Gastric or Duodenal Ulcers","COMPLETED","2023-06-02",{"date":60,"type":52},"2023-06-07",{"date":62,"type":52},"2016-09-01",{"date":64,"type":52},"2020-04-30",{"name":5,"class":6},1]